Ethris Doses First Patient in Phase 2a Clinical Trial of Lead mRNA Candidate ETH47 for Asthma
August 5, 2025
Ethris GmbH, a biotech company that works on developing RNA-based medicines and vaccines, has started giving treatment to patients in a Phase 2a trial for
